KOL Event on aneurysmal Subarachnoid Hemorrhage (aSAH) ...

Research analysts at HC Wainwright issued their FY2025 EPS estimates for Grace Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat ...

GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported fiscal year (FY) third quarter results following a series of announcements regarding conference participation, ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

The upfront net proceeds from this private placement will also be allocated for general corporate purposes. The injectable formulation of nimodipine is in clinical stages, being developed for IV ...

The injectable formulation of nimodipine is in clinical stages, being developed for IV infusions in patients with aneurysmal subarachnoid haemorrhage (aSAH), a type of stroke caused by the rupture ...

Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...

GTx-104 reduced clinically significant hypotension by 19% versus oral nimodipine (28% vs. 35%) in aSAH patients. 54% of GTx-104 patients maintained 95%+ relative dose intensity versus 8% on oral ...

10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a ...

(Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...

NIMOTOP (nimodipine) is a calcium channel blocker indicated for patients with subarachnoid hemorrhage. It improves neurological outcome by relaxing cerebral smooth muscle vasculature and ...